Business
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting
Oral and Poster Presentations to Highlight Clinical Data for I/ONTAK (E7777) Study in Relapsed or Refractory Cutaneous T-cell Lymphoma on December 11, 2022
About this update from Citius Pharmaceuticals, Inc.
[{"type":"text","content":"Oral and Poster Presentations to Highlight Clinical Data for I/ONTAK (E7777) Study in Relapsed or Refractory Cutaneous T-cell Lymphoma on December 11, 2022\nCRANFORD, N.J., Nov. 9, 2022 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (\"Citius\" or the \"Company\") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today announced that abstracts for I/ONTAK (E7777) for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) have been accepted for presentations at the prestigious 64th American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans, December 10-13, 2022.\nDr. Francine Foss, Professor of Medicine in the Section of Medical Oncology at the Yale Cancer Center, and world-renowned expert in T-cell lymphomas, will deliver an oral presentation reviewing the efficacy and safety results of the completed I/ONTAK (E7777) Phase 3 study.\nDr. Christiane Querfeld, Professor of Dermatology and Dermatopathology at City of Hope Cancer Center, and Director of City of Hope's multidisciplinary Cutaneous Lymphoma Program will present a poster highlighting the safety and tolerability data of I/ONTAK (E7777) in patients with relapsed or refractory cutaneous T-cell lymphoma from Study 302. Dr. Querfeld is one of the world's foremost experts in the diagnosis and management of cutaneous lymphomas.\nOral Presentation: \nEfficacy and Safety of E7777 (improved purity denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302\nPublication Number:\n618\nSession Name: \n624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Mature T-cell Malignancies: Clinical and Epidemiological\nDate:\nSunday, December 11, 2021\nSession Time:\n4:30 – 6:00 PM ET\nPresentation Time:\n5:45PM ET\nRoom: \nErnest N. Morial Convention Center, 393-396\nPresenter: \nFrancine Foss, M.D., Yale Cancer Center, New Haven, CT\n \nPoster Presentation: \nSafety and Tolerability of E7777 (improved purity denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302\nPublication Number:\n2927\nSession Name:\n624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster II\nDate:\nSunday, Dece...